Potassium Chloride Tablet, Extended Release
NDC Package 24979-232-01
Package Information
Potassium Chloride tablets is a medication a mineral supplement used to treat or prevent low amounts of potassium in the blood. This formulation utilizes a tablet, extended release delivery system. Marketed by Upsher-smith Laboratories, Llc, this product is identified by NDC 24979-232 and is authorized under FDA application ANDA209688.
Identification & Billing
- RxCUI: 198116 - potassium chloride 20 MEQ Extended Release Oral Tablet
- RxCUI: 198116 - K+ Chloride 20 MEQ Extended Release Oral Tablet
- RxCUI: 198116 - Pot Chloride 20 MEQ Extended Release Oral Tablet
- RxCUI: 198116 - potassium chloride 1500 MG (potassium 20 mEq) Extended Release Oral Tablet
- RxCUI: 198116 - potassium chloride 1500 MG Extended Release Oral Tablet
Clinical Specifications
- Increased Large Intestinal Motility - [PE] (Physiologic Effect)
- Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Osmotic Activity - [MoA] (Mechanism of Action)
- Osmotic Laxative - [EPC] (Established Pharmacologic Class)
- Potassium Compounds - [CS]
- Potassium Salt - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 24979 - Upsher-smith Laboratories, Llc
- 24979-232 - Potassium Chloride
- 24979-232-01 - 100 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC
- 24979-232 - Potassium Chloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (24979-232). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 24979-232-01 identifies a specific commercial package of 100 tablet, extended release in 1 bottle, plastic of Potassium Chloride Extended-release, a human prescription drug labeled by Upsher-smith Laboratories, Llc. This tablet, extended release is formulated for oral use and contains potassium chloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Upsher-smith Laboratories, Llc on April 10, 2023. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood. A normal level of potassium in the blood is important. Potassium helps your cells, kidneys, heart, muscles, and nerves work properly. Most people get enough potassium by eating a well-balanced diet. Some conditions that can lower your body's potassium level include severe prolonged diarrhea and vomiting, hormone problems such as hyperaldosteronism, or treatment with "water pills"/diuretics.
How is this Upsher-smith Laboratories, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 24979023201. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.